To include your compound in the COVID-19 Resource Center, submit it here.

Revlimid lenalidomide: Additional Phase III data

Additional data from the double-blind, international Phase III MM-015 trial in 455 subjects showed that the Revlimid arms had an increase in hematological malignancies but a decreased risk in second

Read the full 303 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE